Home > News > pSivida Limited: Rights Issue to Fund Trials
May 2nd, 2006
pSivida Limited: Rights Issue to Fund Trials
Abstract:
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced details of a Non-Renounceable Rights Issue offering one new ordinary share for every eight shares held at May 22 ("the Record Date") at an issue price of AU$0.60 per share. Capital raised from this Rights Issue will primarily fund the phase III clinical trials of Medidur(TM) for the treatment of Diabetic Macular Edema (DME), and phase IIa clinical trials of our lead BioSilicon(TM) product, BrachySil(TM) which is being developed for the treatment of inoperable pancreatic cancer.
Source:
businesswire
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||